MBL(Mannose binding lectine)-studie.

MBL and prediction of risk on chemotherapy induced febrile neutropenia in patients with a solid tumor.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24964

Enrollment

243

Registered

2012-04-03

Start date

2012-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with chemotherapy for a solid tumor Patienten die behandeling krijgen met chemotherapie vanwege een solide tumor

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients commencing chemotherapy treatments for a solid tumor; 2. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous participation in the current study; 2. Patients < 18 yrs; 3. Patients not able to give informed consent; 4. Patients receiving chemotherapy in a weekly schedule or a bi-weekly dose dense schedule; 5. Patients receiving granulocyte growth factor support (G-CSF); 6. Patients receiving a treatment with an individualized risk (combination of scheme and presence of risk factors) on FN over 20% according to the EORTC guidelines; 7. Patients receiving (prophylactic) antibiotics; 8. Patients receiving concomittant radiotherapy.

Design outcomes

Primary

Measure	Time frame
Relation between baseline MBL and incidence of febrile neutropenia (FN).	—

Secondary

Measure	Time frame
1. MBL genotype and relation FN; 2. Changes in MBL concentration; 3. Relate severity of FN with MBL levels.	—

Contacts

Public ContactA.P. Hamberg

Sint Franciscus Gasthuis

p.hamberg@sfg.nl+31 (0)10 4616145

Outcome results